MK-1200 in Participants with Advanced Solid Tumors
The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with certain types of gastric cancer, esophageal cancer, biliary tract cancer and pancreatic ductal adenocarcinoma that have received and progressed on or after 1 or 2 prior lines of therapy for their cancer. In this study, you will receive an investigational trial drug named MK-1200. All trial participants will get MK-1200 but the dose of MK-1200 you receive will depend on when you join the trial and your type of cancer. You, your trial doctor, and the trial staff will know what dose you are getting of the investigational trial drug, MK-1200. MK-1200 is experimental. It has not been approved to treat any type of cancer. This trial is being done to test the safety and efficacy of the investigational trial drug and see how different doses of the investigational trial drug may work and if it is tolerated by the body. MK-1200 is given once every 2 weeks by a needle in a vein. This is called intravenous (IV) infusion.
The trial has 3 phases: screening, trial treatment, and follow-up. First, the trial staff will see if you can be in the trial. This is called the screening phase and will last about 1 month (28 days). If you can be in the trial, the next step is the trial treatment phase. You will remain in this phase as long as your cancer does not get worse, you are tolerating the investigational trial drug, you do not start a new cancer treatment, or the trial doctor recommends that you stop getting the investigational trial drug. After you stop getting the investigational trial drug, you will enter the follow-up phase. The trial doctor or staff will discuss this schedule with you as the follow up schedule will be dependent on the reason you stopped getting the investigational trial drug.)
If you are eligible and enroll in this clinical trial you may need to provide blood samples, scans (CT, MRI, or PET), echocardiogram/ECG to monitor the heart, and tumor biopsy.
How long you are in the trial depends on your health and how well you tolerate the investigational trial drug. After you stop having trial visits, the trial doctor or staff will contact you about every 12 weeks (3 months) or more frequently to check on your health.
Additional information found here: https://www.clinicaltrials.gov/study/NCT06242691?titles=MK-1200&rank=1
For questions, contact:
uvacancertrials@hscmail.mcc.virginia.edu
No Compensation